Shionogi Of Japan Working To Become Multinational
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi has ambitious plans to transform itself into a multinational company in the pharmaceutical industry. It has five drugs in middle- to late-stage clinical trials in its three areas of concentration - infectious diseases and metabolic and pain syndromes. A new Shionogi administration took over the company April 1 and set goals for itself through its 2009 fiscal year. In the past the company has relied on ties to other multinationals for most of its earnings, but patents on most of those drugs are due to expire within the next 10 years. Already in the current fiscal year, Shionogi has seen its U.S. sales out-number sales in its home country. (Click here for more - a subscription may be required